|
93
|
268
|
4jl4A |
Crystal structure of the complex between ppargamma lbd and the ligand lj570 [(2s)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid] |
|
89
|
245
|
4iu7A |
Crystal structure of the estrogen receptor alpha ligand-binding domain in complex with constrained way-derivative, 2b |
|
93
|
239
|
4jyiA |
Crystal structure of rarbeta lbd in complex with selective partial agonist bms641 [3-chloro-4-[(e)-2-(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl)ethenyl]benzoic acid] |
|
92
|
246
|
4ivwA |
Crystal structure of the estrogen receptor alpha ligand-binding domain in complex with constrained way-derivative, 6b |
|
95
|
299
|
4ia1A |
Diastereotopic and deuterium effects in gemini |
|
86
|
244
|
4iw8A |
Crystal structure of the estrogen receptor alpha ligand-binding domain in complex with dynamic way-derivative, 9a |
|
94
|
239
|
4jygA |
Crystal structure of rarbeta lbd in complex with agonist bms411 [4-{[(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl)carbonyl]amino}benzoic acid] |
|
99
|
318
|
4j5xA |
Crystal structure of the sr12813-bound pxr/rxralpha lbd heterotetramer complex |
|
89
|
245
|
4iw6A |
Crystal structure of the estrogen receptor alpha ligand-binding domain in complex with constrained way-derivative, 7b |
|
85
|
245
|
4ivyA |
Crystal structure of the estrogen receptor alpha ligand-binding domain in complex with dynamic way-derivative, 7a |
|
78
|
244
|
4iuiA |
Crystal structure of the estrogen receptor alpha ligand-binding domain in complex with dynamic way derivative, 4a |
|
90
|
299
|
4ia3A |
Diastereotopic and deuterium effects in gemini |
|
82
|
268
|
4jazA |
Crystal structure of the complex between ppargamma lbd and trans-resveratrol |
|
91
|
298
|
4ia7A |
Diastereotopic and deuterium effects in gemini |
|
81
|
259
|
4j5xC |
Crystal structure of the sr12813-bound pxr/rxralpha lbd heterotetramer complex |
|
98
|
255
|
4iteA |
Crystal structure of the human vitamin d receptor ligand binding domain complexed with 1alpha,25-dihydroxy-2alpha-[2-(2h-tetrazol-2-yl)ethyl]vitamin d3 |
|
103
|
255
|
4itfA |
Crystal structure of the human vitamin d receptor ligand binding domain complexed with 1alpha,25-dihydroxy-2alpha-[2-(1h-tetrazole-1-yl)ethyl]vitamin d3 |
|
100
|
250
|
4hlwA |
Targeting the binding function 3 (bf3) site of the human androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1h-benzoimidazole derivatives. |
|
97
|
268
|
4heeX |
Crystal structure of ppargamma in complex with compound 13 |
|
93
|
299
|
4g2hA |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
95
|
299
|
4g1dA |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
93
|
299
|
4g21A |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
91
|
299
|
4g1zA |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
93
|
297
|
4g20A |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
93
|
299
|
4g1yA |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
100
|
253
|
4g2iA |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
69
|
228
|
3r2aA |
Crystal structure of rxralpha ligand-binding domain complexed with corepressor smrt2 and antagonist rhein |
|
101
|
250
|
4fn9A |
X-ray crystal structure of the ancestral 3-keto steroid receptor - progesterone complex |
|
93
|
271
|
3r5nA |
Crystal structure of ppargammalbd complexed with the agonist magnolol |
|
96
|
298
|
4fhiA |
Development of synthetically accessible non-secosteroidal hybrid molecules combining vitamin d receptor agonism and histone deacetylase inhibition |
|
93
|
299
|
4fhhA |
Development of synthetically accessible non-secosteroidal hybrid molecules combining vitamin d receptor agonism and histone deacetylase inhibition |
|
69
|
229
|
3r29A |
Crystal structure of rxralpha ligand-binding domain complexed with corepressor smrt2 |
|
98
|
248
|
4fneA |
X-ray crystal structure of the ancestral 3-keto steroid receptor - doc complex |
|
74
|
232
|
3r5mA |
Crystal structure of rxralphalbd complexed with the agonist magnolol |
|
95
|
270
|
4fgyA |
Identification of a unique ppar ligand with an unexpected binding mode and antibetic activity |
|
100
|
271
|
3qt0A |
Revealing a steroid receptor ligand as a unique ppargamma agonist |
|
94
|
246
|
3q95A |
Crystal structure of human estrogen receptor alpha lbd in complex with grip peptide and estriol |
|
90
|
253
|
3q95B |
Crystal structure of human estrogen receptor alpha lbd in complex with grip peptide and estriol |
|
102
|
273
|
3po9A |
Crystal structure of ppargamma ligand binding domain in complex with tripropyltin |
|
86
|
229
|
3p88A |
Fxr bound to isoquinolinecarboxylic acid |
|
103
|
267
|
3peqA |
Ppard complexed with a phenoxyacetic acid partial agonist |
|
83
|
225
|
3p89A |
Fxr bound to a quinolinecarboxylic acid |
|
85
|
230
|
3pcuA |
Crystal structure of human retinoic x receptor alpha ligand-binding domain complexed with lx0278 and src1 peptide |
|
93
|
239
|
3plzA |
Human lrh1 lbd bound to gr470 |
|
103
|
255
|
3p8xA |
Synthesis, structure, and biological activity of des-side chain analogues of 1alpha,25-dihydroxyvitamin d3 with substituents at c-18 |
|
106
|
278
|
3prgA |
Ligand binding domain of human peroxisome proliferator activated receptor |
|
98
|
273
|
3pbaA |
Crystal structure of ppargamma ligand binding domain in complex with monosulfate tetrabromo-bisphenol a (monotbbpa) |
|
92
|
266
|
3oz0A |
Ppar delta in complex with azppard02 |
|
86
|
240
|
3os9A |
Estrogen receptor |
|
101
|
254
|
3ogtA |
Design, chemical synthesis, functional characterization and crystal structure of the sidechain analogue of 1,25-dihydroxyvitamin d3. |
